We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+31.98%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$3.11B
AUM Growth
+$217M
Cap. Flow
-$278M
Cap. Flow %
-8.93%
Top 10 Hldgs %
51.56%
Holding
91
New
16
Increased
7
Reduced
4
Closed
14

Top Buys

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$76.3M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$56M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$42.7M
4
CYTK icon
Cytokinetics
CYTK
+$38.4M
5
ALGS icon
Aligos Therapeutics
ALGS
+$29.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$383M
2
ALLK
Allakos
ALLK
+$55M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.8M
4
CGEN icon
Compugen
CGEN
+$38.7M
5
QURE icon
uniQure
QURE
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
26
Solid Biosciences
SLDB
$794M
$32.1M 1.03%
282,305
+180,180
+176% +$11.4M
PAND
27
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$31.3M 1.01%
2,107,513
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.42B
$30.8M 0.99%
2,202,812
– –
AMRN
29
Amarin Corp
AMRN
$298M
$29.3M 0.94%
300,000
-50,000
-14% -$4.82M
MRNS
30
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$29.3M 0.94%
2,400,000
– –
RNAM
31
DELISTED
Avidity Biosciences
RNAM
$28.6M 0.92%
1,121,327
– –
ANAB icon
32
AnaptysBio
ANAB
$1.58B
$27.9M 0.9%
1,300,000
– –
PRVL
33
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$25.9M 0.83%
1,123,105
– –
KDMN
34
DELISTED
Kadmon Holdings, Inc.
KDMN
$25.8M 0.83%
6,205,882
– –
MRUS
35
DELISTED
Merus
MRUS
$25M 0.8%
+1,427,849
New +$21.1M
GOSS icon
36
Gossamer Bio
GOSS
$82.9M
$24.8M 0.8%
2,562,358
– –
BCAB icon
37
BioAtla
BCAB
$5.46M
$23.3M 0.75%
+13,727
New +$22.9M
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
$23M 0.74%
4,000,000
– –
MREO
39
Mereo BioPharma
MREO
$54.7M
$22.3M 0.72%
6,226,673
+2,197,024
+55% +$5.5M
BMRN icon
40
BioMarin Pharmaceuticals
BMRN
$11.6B
$21.9M 0.7%
250,000
– –
AKRO
41
DELISTED
Akero Therapeutics
AKRO
$21.5M 0.69%
831,495
– –
NGNE icon
42
Neurogene
NGNE
$656M
$21.2M 0.68%
75,053
– –
PNT
43
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$20.9M 0.67%
1,500,000
– –
CABA icon
44
Cabaletta Bio
CABA
$437M
$20M 0.64%
1,603,361
+37,000
+2% +$480K
CDAK
45
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$19.5M 0.63%
+602,650
New +$7.97M
CERE
46
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$18.4M 0.59%
+1,314,500
New +$17.1M
CLDX icon
47
Celldex Therapeutics
CLDX
$2.99B
$17.5M 0.56%
1,000,000
– –
MIST icon
48
Milestone Pharmaceuticals
MIST
$138M
$16.6M 0.53%
2,477,194
+700,000
+39% +$4.69M
MTNB icon
49
Matinas BioPharma
MTNB
$1.88M
$15.6M 0.5%
229,573
– –
PSTX
50
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$13.7M 0.44%
1,251,055
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Boxer Capital held 91 positions worth $3.11B, up 7.5% from $2.89B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital withdrew a net $278M in Q4 2020, closing 14 positions and reducing 4 holdings. Its most notable exit was Immunomedics Inc, an estimated $383M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Boxer Capital opened a new position in ARS Pharmaceuticals worth $77.6M.

  • Boxer Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 1,675,377 shares worth $77.6M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q4 2020, an estimated $76.3M increase.
  • Boxer Capital's biggest Q4 2020 reduction was uniQure, cutting an estimated $21.7M.
  • Boxer Capital fully exited Immunomedics Inc in Q4 2020, selling an estimated $383M.
  • Boxer Capital's ten largest holdings make up 52% of its $3.11B portfolio in Q4 2020.
  • Boxer Capital opened 16 new positions and closed 14 in Q4 2020.
  • Boxer Capital's portfolio value rose 7.5% quarter-over-quarter to $3.11B.

Based on Boxer Capital's 13F filing for Q4 2020, filed 16 Feb 2021.